Literature DB >> 8389669

Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer.

K Kawajiri1, K Nakachi, K Imai, J Watanabe, S Hayashi.   

Abstract

The p53 tumor suppressor gene is mutated in diverse types of human cancer, and the normal allele encodes a nuclear protein that regulates expression of cell cycle-related genes as a transcription factor. The wild-type of p53 protein exists as at least two forms of variants among human populations, ascribed to amino acid replacement at codon 72 of Arg by Pro. In this study, we show that this germ line Arg-Pro polymorphism at codon 72 of the p53 gene is associated with genetically determined susceptibility to smoking-induced lung cancer; a susceptible genotype Pro/Pro has a 1.7-fold higher risk of this cancer compared with other genotypes. This p53 polymorphism modulates risk to smoking-induced lung cancer independently of other genetic risk factors such as germ line polymorphism of CYP1A1 or GST1 genes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8389669     DOI: 10.1093/carcin/14.6.1085

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  34 in total

1.  DNA sequence variants of p53: cancer and aging.

Authors:  Y Sun; C Keshava; D S Sharp; A Weston; E C McCanlies
Journal:  Am J Hum Genet       Date:  1999-12       Impact factor: 11.025

Review 2.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

3.  The p53 status in juvenile chronic arthritis and rheumatoid arthritis.

Authors:  H Taubert; B Thamm; A Meye; F Bartel; A K Rost; D Heidenreich; V John; J Brandt; M Bache; P Würl; H Schmidt; D Riemann
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

4.  P53 Codon 72 polymorphisms: a case-control study of gastric cancer and potential interactions.

Authors:  James Sul; Guo-Pei Yu; Qing-Yi Lu; Ming-Lan Lu; Veronica Wendy Setiawan; Ming-Rong Wang; Chun Hua Guo; Shun-Zhang Yu; Lina Mu; Lin Cai; Robert C Kurtz; Zuo-Feng Zhang
Journal:  Cancer Lett       Date:  2005-08-19       Impact factor: 8.679

5.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

Review 6.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

7.  The discrepancy between genetic polymorphism of p53 codon 72 and the expression of p53 protein in Helicobacter pylori-associated gastric cancer in Korea.

Authors:  Nayoung Kim; Sung-Il Cho; Hye Seung Lee; Ji Hyun Park; Jee Hyun Kim; Joo Sung Kim; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-01-29       Impact factor: 3.199

Review 8.  Genetic unraveling of colorectal cancer.

Authors:  Sabha Rasool; Vamiq Rasool; Tahira Naqvi; Bashir A Ganai; Bhahwal Ali Shah
Journal:  Tumour Biol       Date:  2014-02-27

9.  A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism.

Authors:  Zun-Wu Zhang; Paul Newcomb; Andrew Hollowood; Jyoti Gupta; Roger Feakins; Alan Storey; Michael J G Farthing; Derek Alderson; Jeff Holly
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

10.  Glutathione S-transferase GSTM1, GSTT1 and p53 codon 72 polymorphisms in human tumor cells.

Authors:  Masatsugu Ueda; Yao-Ching Hung; Yoshito Terai; Koji Kanda; Mikio Takehara; Hikari Yamashita; Hiroyuki Yamaguchi; Daisuke Akise; Masayuki Yasuda; Koji Nishiyama; Minoru Ueki
Journal:  Hum Cell       Date:  2003-12       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.